The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Osipenko M.F.

Novosibirsk State Medical University, Russian Ministry of Health

Shrainer E.V.

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences Novosibirsk, Russia

Parfenov A.I.

GBUZ "Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr" Departamenta zdravookhraneniia Moskvy

Successes and unsolved problems in the study of celiac disease

Authors:

Osipenko M.F., Shrainer E.V., Parfenov A.I.

More about the authors

Journal: Therapeutic Archive. 2016;88(2): 97‑100

Read: 2322 times


To cite this article:

Osipenko MF, Shrainer EV, Parfenov AI. Successes and unsolved problems in the study of celiac disease. Therapeutic Archive. 2016;88(2):97‑100. (In Russ.)
https://doi.org/10.17116/terarkh201688297-100

References:

  1. Sapone A, Bai JC, Ciacci C, Dolinsek J et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classication. BMC Med. 2012;10:13.  doi:10.1186/1741-7015-10-13.
  2. McAllister CS, Kagnoff MF. The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. Semin Immunopathol. 2012;34:581-600. doi:10.10071900281-012-0318-8.
  3. Drago S, El Asmar R, Di Pierro M et al. Gliadin, zonulin and permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. 2006;41:408-419.  doi:10.1080/00365520500235334.
  4. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity and cancer. Physiol Rev. 2011;91:151-175.  doi:10.1152/physrev.00003.2008.
  5. McAllister CS, Kagnoff MF. The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. Semin Immunopathol. 2012;34:581-600.  doi:10.10071900281-012-0318-8.
  6. Odii BO, Coussons P. Biological functionalities of transglutaminase and the possibility of its compensation by other members of transglutaminase family. Scientific World J. 2014;2014. ID 714561. doi:10.1155/2014/714561.
  7. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in CD. J. Cell Biol. 2008;180(1):i1-i1. doi:10.1083/jcb1801oia1.
  8. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nature Clin Pract Gastroenterol Hepatol. 2005;2(39):416-422.  doi:10.1038/ncpgasthep0259.
  9. Sabel'nikova E.A., Parfenov A.I., Krums L.M., Gudkova R.B, Sagynbaeva V.E., Bykova S.V. Znachenie metoda opredeleniya deamidirovannogo peptida gliadina v diagnostike tseliakii. Terapevticheskii arkhiv. 2014;86(2):39-43.
  10. Schumann M, Richter JF, Wedell I et al. Mechanisms of epithelial translocation of the alpha — gliadin-33mer in coeliac sprue. Gut. 2008;57:747-754.  doi:10.1136/gut.2007.136366.
  11. Sellitto M, Bai G, Serena G et al. Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. PloS ONE. 2012;7(3). doi:10.1371/journal.pone.0033387.
  12. Palmer C, Bik E, DiGiulio D, Relman D, Brown P. Development of the Human Infant Intestinal Microbiota. Plos Biol. 2007;5(7):e177. doi:10.1371/journal.pbio.0050177.
  13. Miyara M, Sakaguchi S. Human FoxP3+CD4+ regulatory T cells: their knowns and unknowns. Immunol Cell Biol. 2011;89(3):346-351.  doi:10.1038/icb.2010.137.
  14. Forsberg G, Fahlgren A, Horstedt P, Hammarstrom S, Hernell O, Hammarstrom M. Presence of Bacteria and Innate Immunity of Intestinal Epithelium in Childhood Celiac Disease. Am J Gastroenterol. 2004;99(5):894-904.  doi:10.1111/j.1572-0241.2004.04157.x.
  15. Nadal I, Donant E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol. 2007;56(12):1669-1674. doi:10.1099/jmm.0.47410-0.
  16. Sánchez E, Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Reduced diversity and increased virulence-gene carriage in intestinal enterobacteria of coeliac children. BMC Gastroenterol. 2008;8(1):50.  doi:10.1186/1471-230x-8-50.
  17. Collado M, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiol. 2008;8(1):232.  doi:10.1186/1471-2180-8-232.
  18. Sanz Y, Sánchez E, Marzotto M, Calabuig M, Torriani S, Dellaglio F. Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. FEMS Immunol Med Microbiol. 2007;51(3):562-568.  doi:10.1111/j.1574-695x.2007.00337.x.
  19. Rostami Nejad M, Rostami K, Yamaoka Y, Mashayekhi R, Molaei M, Dabiri H, Al Dulaimi D, Mirsattari D, Zojaji H, Norouzinia M, Zali MR. Clinical and histological presentation of Helicobacter pylori and gluten related gastroenteropathy. Arch Iran Med. 2011;14:115-118. doi:011142/aim.009.
  20. Vasil'ev Yu.V., Parfenov D.A. Osobennosti khronicheskogo gastrita pri glyutenovoi enteropatii. Rossiiskii gastroenterologicheskii zhurnal. 1995;2:37-41.
  21. Rostami-Nejad M, Villanacci V, Mashayakhi R et al. Celiac disease and Hp infection association in Iran. Rev Espenferm Dig. 2009;101(12). doi:10.4321/s1130-01082009001200004.
  22. Ciacci C, Squillante A, Rendina D et al. Helicobacter pylori infection and peptic disease in coeliac disease. Eur J Gastroenterol Hepatol. 2000;12(12):1283-1287. doi:10.1097/00042737-200012120-00004.
  23. Diamanti A, Maino C, Niveloni S et al. Characterization of gastric mucosal lesions in patients with celiac disease: a prospective controlled study. Am J Gastroenterol. 1999;94(5):1313-1319. doi:10.1111/j.1572-0241.1999.01082.x.
  24. Aydogdu S, Cakir M, Ali Yuksekkaya H et al. Helicobacter pylori infection in children with celiac disease. Scand J Gastroenterol. 2008;43(9):1088-1093. doi:10.1080/00365520802101846.
  25. Luzza F, Mancuso M, Imeneo M et al. Helicobacter pylori Infection in Children with Celiac Disease: Prevalence and Clinicopathologic Features. J Pediat Gastroenterol Nutr. 1999;28(2): 143-146.  doi:10.1097/00005176-199902000-00009.
  26. Crabtree J, O’Mahony S, Wyatt J et al. Helicobacter pylori serology in patients with coeliac disease and dermatitis herpetiformis. J Clin Pathol. 1992;45(7):597-600.  doi:10.1136/jcp.45.7.597.
  27. Konturek P, Karczewska E, Dieterich W, Hahn E, Schuppan D. Increased prevalence of Helicobacter pylori infection in patients with celiac disease. Am J Gastroenterol. 2000;95(12):3682-3683. doi:10.1111/j.1572-0241.2000.03421.x.
  28. Chen Y. Inverse Associations of Helicobacter pylori With Asthma and Allergy. Arch Intern Med. 2007;167(8):821.  doi:10.1001/archinte.167.8.821.
  29. Arnold I, Dehzad N, Reuter S et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Investigat. 2011;121(8):3088-3093. doi:10.1172/jci45041.
  30. Chen Y, Segers S, Blaser M. Association between Helicobacter pylori and mortality in the NHANES III study. Gut. 2013;62(9):1262-1269. doi:10.1136/gutjnl-2012-303018.
  31. Catassi C, Kryszak D, Bhatti B et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42(7):530-538.  doi:10.3109/07853890.2010.514285.
  32. Ludvigsson J, Leffler D, Bai J et al. The Oslo definitions for coeliac disease and related terms. Gut. 2012;62(1):43-52.  doi:10.1136/gutjnl-2011-301346.
  33. Parfenov A.I. Novye gorizonty izucheniya chuvstvitel'nosti k glyutenu. Terapevticheskii arkhiv. 2013;85(2):4-7.
  34. Ludvigsson J, Card T, Kaukinen K et al. Screening for celiac disease in the general population and in high-risk groups. United Eur Gastroenterol J. 2014;3(2):106-120.  doi:10.1177/2050640614561668.
  35. Catassi C, Bai J, Bonaz B et al. Non-Celiac Gluten Sensitivity: The New Frontier of Gluten Related Disorders. Nutrients. 2013;5(10):3839-3853. doi:10.3390/nu5103839.
  36. Carroccio A, Mansueto P, Iacono G et al. Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity. Am J Gastroenterol. 2012;107(12):1898-1906. doi:10.1038/ajg.2012.236.
  37. Biesiekierski J, Newnham E, Shepherd S, Muir J, Gibson P. Characterization of Adults With a Self-Diagnosis of Nonceliac Gluten Sensitivity. Nutrit Clin Pract. 2014;29(4):504-509.  doi:10.1177/0884533614529163.
  38. Biesiekierski J, Iven J. Non-coeliac gluten sensitivity: piecing the puzzle together. United Eur Gastroenterol J. 2015;3(2):160-165.  doi:10.1177/2050640615578388.
  39. Pinier M, Fuhrmann G, Verdu E, Leroux J. Prevention Measures and Exploratory Pharmacological Treatments of Celiac Disease. Am J Gastroenterol. 2010;105(12):2551-2561. doi:10.1038/ajg.2010.372.
  40. Wieser H, Koehler P. Detoxification of Gluten by Means of Enzymatic Treatment. J AOAC Int. 2012;95(2):356-363.  doi:10.5740/jaoacint.sge_wieser.
  41. Leffler D, Kelly C, Abdallah H et al. A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge. Am J Gastroenterol. 2012;107(10):1554-1562. doi:10.1038/ajg.2012.211.
  42. Galipeau H, Wiepjes M, Motta J et al. Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders. Am J Gastroenterol. 2014;109(5):748-756.  doi:10.1038/ajg.2014.48.
  43. Leffler D, Kelly C, Abdallah H et al. A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge. Am J Gastroenterol. 2012;107(10):1554-1562. doi:10.1038/ajg.2012.211.
  44. Galipeau H, Wiepjes M, Motta J et al. Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders. The American Journal of Gastroenterology. 2014;109(5):748-756.  doi:10.1038/ajg.2014.48.
  45. Sabel'nikova E.A., Krums L.M., Parfenov A.I., Vorob'eva N.N., Gudkova R.B. Osobennosti reabilitatsii bol'nykh glyutenchuvstvitel'noi tseliakiei. Terapevticheskii arkhiv. 2013;85(1):103-107.
  46. Croese J, Gaze S, Loukas A. Changed gluten immunity in celiac disease by Necatoramericanus provides new insights into autoimmunity. Int J Parasitol. 2013;43(3-4):275-282.  doi:10.1016/j.ijpara.2012.12.005.
  47. Sollid L, Khosla C. Novel therapies for coeliac disease. J Int Med. 2011;269(6):604-613.  doi:10.1111/j.1365-2796.2011.02376.x.
  48. A Phase II Study of CCX282-B in Patients With Celiac Disease — Full Text View — ClinicalTrials.govhttp://clinicaltrials.gov/ct2/show/NCT00540657 Access date 20.06.2015
  49. ImmusanThttp://www.immusant.com/ Access date: 20.06.2015

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.